Trastuzumab beyond progression: a cost-utility analysis.

Matter-Walstra KW, Dedes KJ, Schwenkglenks M, Brauchli P, Szucs TD, Pestalozzi BC

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
20444849

DOI
10.1093/annonc/mdq250

Indexing Status
Subject indexing assigned by NLM

MeSH
Antibodies, Monoclonal /administration & dosage; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols /therapeutic use; Breast Neoplasms /drug therapy /economics /mortality; Capecitabine; Cost-Benefit Analysis /economics; Costs and Cost Analysis; Deoxycytidine /administration & dosage /analogs & derivatives; Disease Progression; Female; Fluorouracil /administration & dosage /analogs & derivatives; Humans; Lymphatic Metastasis; Markov Chains; Prognosis; Quality-Adjusted Life Years; Sensitivity and Specificity; Survival Rate; Time Factors; Trastuzumab

AccessionNumber
22010002016

Date bibliographic record published
23/02/2011